A significant scientific milestone was reached Monday, August 23 when the Pfizer COVID-19 vaccine, Comirnaty, garnered full FDA approval. According to the FDA press conference, after reviewing the full application, the FDA determined that the benefits of the Pfizer COVID-19 vaccine outweigh the risks for individuals 16 years of age and older. The Pfizer vaccine is the third COVID-19 vaccine to be approved by the FDA, and it joins the mRNA vaccines developed by Moderna and BioNTech-Pfizer. The FDA approval of the Pfizer vaccine is a major development in the battle against COVID-19 and marks a significant step forward in the efforts to control the pandemic.

The Pfizer vaccine is based on a novel technology known as messenger RNA (mRNA). The mRNA is designed to mimic the genetic code of the COVID-19 virus, allowing the body to recognize and fight off the virus. The vaccine is administered in two doses, with the second dose given approximately four weeks after the first. The FDA's review of the Pfizer vaccine was based on clinical trial data from more than 44,000 participants, who were followed for up to 12 months. The data showed that the vaccine was 91% effective in preventing COVID-19 among those who received it.

The FDA approval of the Pfizer vaccine is a major development in the battle against COVID-19 and marks a significant step forward in the efforts to control the pandemic. The vaccine is currently being distributed to healthcare workers and older adults, and the FDA is expected to authorize its use for younger adults in the near future. With the approval of the Pfizer vaccine, the United States is one step closer to achieving herd immunity and returning to a more normal way of life.

As Dean of the College of Science, one could say I've had a rather unique and predominantly scientific view of the COVID-19 pandemic race. I've been involved in modeling the spread of the virus, analyzing the effectiveness of different interventions, and studying the impact of the pandemic on society. I've also been involved in research on new treatments and vaccines, and I've been working with my team to develop strategies to prevent the spread of the virus in the future.

But, here's more data...